Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Issue 23 (10th September 2013)

• Record Type: Journal Article
• Authors: Okuwaki, Kosuke; Kida, Mitsuhiro; Mikami, Tetuo; Yamauchi, Hiroshi; Imaizumi, Hiroshi; Miyazawa, Shiro; Iwai, Tomohisa; Takezawa, Miyoko; Saegusa, Makoto; Watanabe, Masahiko; Koizumi, Wasaburo
• Is Part Of: Cancer. Volume 119:Issue 23(2013)
• Page Start: 4094
• Page End: 4102
• Publication Date: 2013-09-10
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28341
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28341-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>The impact of somatostatin receptor type 2 (SSTR‐2a) expression levels on outcomes in patients with pancreatic neuroendocrine tumors (PNETs) has not been evaluated.</p> </sec> <sec id="cncr28341-sec-0002" sec-type="section"> <title>METHODS</title> <p>Correlations between clinicopathologic characteristics, including SSTR‐2a expression and outcomes, were retrospectively studied in 79 patients with pancreatic neuroendocrine tumors (PNETs).</p> </sec> <sec id="cncr28341-sec-0003" sec-type="section"> <title>RESULTS</title> <p>The SSTR‐2a score was 0 in 27% of patients, 1 in 24% of patients, 3 in 30% of patients, and 4 in 18% of patients. The overall survival rate was 87% at 1 year, 77% at 3 years, and 71% at 5 years. On univariate analysis, a pancreatic tumor that measured ≥20 mm in greatest dimension, stage IV disease, vascular invasion, neuroendocrine carcinoma (NEC), and an SSTR‐2a score of 0 were associated significantly with poor outcomes. On multivariate analysis, NEC (<italic>P</italic> = .000; hazard ratio, 28.8; 95% confidence interval, 7.502‐111.240) and an SSTR‐2a score of 0 (<italic>P</italic> = .001; hazard ratio, 3.611; 95% confidence interval, 1.344‐9.702) were related independently to poor outcomes.</p> </sec> <sec id="cncr28341-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The current analysis of prognostic factors in patients with PNETs demonstrated that NEC and an SSTR‐2a score of 0 both were significant independent predictors of poor outcomes. The results suggest that the assessment of SSTR‐2a may facilitate the selection of treatment regimens and the prediction of outcomes. Because a considerable proportion of patients with NEC have SSTR‐2a‐positive tumors, further analyses of the usefulness of somatostatin analogues are warranted in patients who have SSTR‐2a‐positive NEC. Cancer 2013. © 2013 American Cancer Society.</p> </sec> </abstract>